Johnson & Johnson $JNJ Shares Sold by Interchange Capital Partners LLC

Interchange Capital Partners LLC decreased its position in Johnson & Johnson (NYSE:JNJ) by 4.8% during the 2nd quarter, Holdings Channel reports. The fund owned 4,518 shares of the company’s stock after selling 230 shares during the quarter. Interchange Capital Partners LLC’s holdings in Johnson & Johnson were worth $690,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in the company. Brighton Jones LLC raised its holdings in Johnson & Johnson by 7.1% during the second quarter. Brighton Jones LLC now owns 57,751 shares of the company’s stock worth $8,822,000 after purchasing an additional 3,807 shares in the last quarter. MQS Management LLC acquired a new stake in Johnson & Johnson during the second quarter worth approximately $669,000. Graybill Wealth Management LTD. raised its holdings in Johnson & Johnson by 1.8% during the second quarter. Graybill Wealth Management LTD. now owns 28,962 shares of the company’s stock worth $4,424,000 after purchasing an additional 505 shares in the last quarter. BIP Alliance LLC raised its holdings in Johnson & Johnson by 10.9% during the second quarter. BIP Alliance LLC now owns 3,105 shares of the company’s stock worth $474,000 after purchasing an additional 306 shares in the last quarter. Finally, AG2R LA Mondiale Gestion D Actifs raised its holdings in Johnson & Johnson by 0.8% during the second quarter. AG2R LA Mondiale Gestion D Actifs now owns 122,049 shares of the company’s stock worth $18,643,000 after purchasing an additional 991 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Insiders Place Their Bets

In related news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the transaction, the executive vice president directly owned 178,013 shares in the company, valued at $31,652,491.53. This trade represents a 24.08% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 0.16% of the stock is currently owned by company insiders.

Johnson & Johnson Stock Performance

Shares of Johnson & Johnson stock opened at $190.38 on Friday. The firm’s fifty day simple moving average is $182.26 and its 200-day simple moving average is $166.25. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $194.48. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.76. The stock has a market capitalization of $458.69 billion, a price-to-earnings ratio of 18.38, a PEG ratio of 2.24 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. The firm had revenue of $24.02 billion for the quarter. As a group, equities analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be given a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date is Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio (DPR) is 50.19%.

Wall Street Analyst Weigh In

JNJ has been the topic of a number of research analyst reports. Piper Sandler reissued an “overweight” rating on shares of Johnson & Johnson in a report on Thursday, July 17th. Loop Capital set a $190.00 price objective on shares of Johnson & Johnson in a report on Wednesday. Barclays lifted their target price on shares of Johnson & Johnson from $165.00 to $176.00 and gave the company an “equal weight” rating in a report on Thursday, July 17th. Daiwa America raised shares of Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a report on Monday, October 20th. Finally, Cowen reaffirmed a “buy” rating on shares of Johnson & Johnson in a report on Tuesday, October 14th. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat, Johnson & Johnson presently has an average rating of “Moderate Buy” and an average target price of $199.05.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.